Amgen's new research and development facility in San Francisco. (courtesy photo) Thousand Oaks-based Amgen saw shares slip 5% on Aug. 7, one day after the company's second-quarter earnings announcement, but analysts remain excited about the large biotech's future pipeline largely led by its obesity-focused treatment. Amgen, one of the largest biotech companies in the world,…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
